Inclusion Criteria:

          -  Have advanced or metastatic cancer (solid tumors) and be an appropriate candidate for
             experimental therapy.

               -  Part B (No Longer Enrolling Participants): Have advanced or metastatic cancer
                  with an activating mitogen-activated protein kinase pathway alteration, BRAF
                  mutant metastatic melanoma refractory to or relapsed after treatment with RAF
                  and/or MEK inhibitors, metastatic melanoma with a NRAS mutation, or BRAF mutant
                  NSCLC.

               -  Part C: Advanced, unresectable cancer (dose escalation) and advanced,
                  unresectable, or metastatic non-small cell lung cancer with a BRAF or RAS
                  mutation, or NRAS mutant melanoma (dose expansion).

               -  Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal
                  adenocarcinoma (dose escalation and dose expansion).

               -  Part E: Metastatic BRAF V600E colorectal cancer.

          -  Have discontinued previous treatments for cancer and have resolution, except where
             otherwise stated in the inclusion criteria, of all clinically significant toxic
             effects of prior chemotherapy, surgery, or radiotherapy to Grade ≤1 by National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

          -  Have adequate organ function.

          -  Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

        Exclusion Criteria:

          -  Have serious preexisting medical conditions.

          -  Have a known human immunodeficiency virus (HIV) infection or known
             activated/reactivated hepatitis A, B, or C.

          -  Have symptomatic central nervous system malignancy or metastasis.

          -  Have current hematologic malignancies, acute or chronic leukemia.

          -  Have a second primary malignancy that in the judgment of the investigator or Lilly may
             affect the interpretation of results.

          -  Have prior malignancies. Participants with carcinoma in situ of any origin and
             participants with prior malignancies who are in remission and whose likelihood of
             recurrence is very low, as judged by the Lilly clinical research physician, are
             eligible for this study.

          -  Have a mean QT interval corrected for heart rate (QTc) of ≥470 milliseconds on
             screening electrocardiogram (ECG) as calculated using the Bazett's formula at several
             consecutive days of assessment.

          -  Have participated, within the last 28 days in a clinical trial involving an
             investigational product or are currently enrolled in a clinical trial involving an
             investigational product or any other type of medical research judged not to be
             scientifically or medically compatible with this study.

          -  Have previously completed or withdrawn from this study or any other study
             investigating an ERK1/2 inhibitor.

          -  If female, is pregnant, breastfeeding, or planning to become pregnant.

          -  Have history or findings of central or branch retinal artery or venous occlusion with
             significant vision loss or other retinal diseases that cause current visual impairment
             or would likely cause visual impairment over the time period of the study.

          -  Currently using concomitant medications that are strong inhibitors or inducers of
             CYP3A4.

          -  Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the
             judgment of the investigator, would preclude participation in this study, including
             interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy.

          -  Part C4 NRAS Melanoma: have previously completed or withdrawn from a study
             investigating a MEK inhibitor.